产品
编 号：F619053
分子式：C17H16N2O3
分子量：296.32
分子式：C17H16N2O3
分子量：296.32
产品类型
规格
价格
是否有货
10mM*1mL in DMSO
询价
询价
1mg
询价
询价
5mg
询价
询价
10mg
询价
询价
50mg
询价
询价
结构图
CAS No: 2231747-03-6
产品详情
生物活性：
OXFBD04 is a potent and selective BRD4 inhibitor with an IC50 of 166?nM. OXFBD04 is a potent BET bromodomain ligand with additional modest affinity for the CREBBP bromodomain. OXFBD04 has anti-cancer activity.
体内研究：
OXFBD04 has optimised physicochemical properties (LE=0.43; LLE=5.74; SFI=5.96), and good metabolic stability (t1/2=388?min). OXFBD04 has CLint of 3.57 μL/min/mg.
体外研究：
OXFBD04 (0.01-100 μM; 48 hours) inhibits cancer cell lines growth. OXFBD04 (10?μM; for 10, 24, or 48?hours) induces MYC suppression in MCF7 breast cancer cells.
OXFBD04 is a potent and selective BRD4 inhibitor with an IC50 of 166?nM. OXFBD04 is a potent BET bromodomain ligand with additional modest affinity for the CREBBP bromodomain. OXFBD04 has anti-cancer activity.
体内研究：
OXFBD04 has optimised physicochemical properties (LE=0.43; LLE=5.74; SFI=5.96), and good metabolic stability (t1/2=388?min). OXFBD04 has CLint of 3.57 μL/min/mg.
体外研究：
OXFBD04 (0.01-100 μM; 48 hours) inhibits cancer cell lines growth. OXFBD04 (10?μM; for 10, 24, or 48?hours) induces MYC suppression in MCF7 breast cancer cells.
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备